Vericel Corp Files 8-K: Financial Statements & Exhibits
Ticker: VCEL · Form: 8-K · Filed: Aug 15, 2024 · CIK: 887359
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
Vericel filed an 8-K with financial docs, nothing major to see here.
AI Summary
On August 15, 2024, Vericel Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant disclosures detailed in the provided text. The report confirms Vericel Corporation's identity, incorporation in Michigan, and principal executive offices in Cambridge, MA.
Why It Matters
This 8-K filing indicates Vericel Corporation is submitting required financial documentation and exhibits to the SEC, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — The filing is a routine submission of financial statements and exhibits, not indicating any new risks or material changes.
Key Numbers
- 001-35280 — SEC File Number (Identifies the company's filing history with the SEC.)
- 94-3096597 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Vericel Corporation (company) — Registrant
- August 15, 2024 (date) — Date of Report
- Michigan (jurisdiction) — State of Incorporation
- 64 Sidney Street, Cambridge, MA 02139 (address) — Principal Executive Offices
- 001-35280 (identifier) — Commission File Number
- 94-3096597 (identifier) — I.R.S. Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of August 15, 2024.
When was Vericel Corporation incorporated?
Vericel Corporation was incorporated in Michigan.
What is Vericel Corporation's principal executive office address?
Vericel Corporation's principal executive office is located at 64 Sidney Street, Cambridge, MA 02139.
What is the Commission File Number for Vericel Corporation?
The Commission File Number for Vericel Corporation is 001-35280.
Does this filing indicate any new material events or agreements?
Based on the provided text, this filing primarily concerns financial statements and exhibits, and does not explicitly detail any new material events or agreements.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-08-15 16:08:47
Filing Documents
- ef20034225_8k.htm (8-K) — 24KB
- ef20034225_ex99-1.htm (EX-99.1) — 26KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-24-037511.txt ( ) — 193KB
- vcel-20240815.xsd (EX-101.SCH) — 4KB
- vcel-20240815_lab.xml (EX-101.LAB) — 21KB
- vcel-20240815_pre.xml (EX-101.PRE) — 16KB
- ef20034225_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On August 15, 2024, Vericel Corporation issued a press release titled "Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns." A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 15, 2024, titled "Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns." 104 Cover Page Interactive Data File (embedded within the Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vericel Corporation Date: August 15, 2024 By: /s/ Sean C. Flynn Name: Sean C. Flynn Title: Chief Legal Officer